Protocols for in vivo measurement of the ion transport defects in cystic fibrosis nasal epithelium

New treatments for cystic fibrosis (CF), including gene therapy, are currently being assessed. These aim to correct the basic defects of increased sodium absorption and decreased chloride secretion in airway epithelia. Assessment of these bioelectric parameters, particularly in the nasal epithelium, is likely to be used as a measure of treatment efficacy. However, the optimal in vivo protocol to discriminate cystic fibrosis from non-cystic fibrosis subjects is unclear. We have, therefore, compared three protocols for measurement of the cystic fibrosis ion transport defects in vivo in the nasal epithelium. Sodium absorption was measured using both the baseline potential difference and the response to the sodium channel blocker, amiloride. Chloride secretion was assessed in the presence of amiloride, using perfusion with isoprenaline, or terbutaline, or a low chloride solution followed by isoprenaline. Baseline potential difference (PD) and the absolute response to amiloride clearly differentiated the increased sodium absorption in the cystic fibrosis subjects. The responses both to terbutaline (delta PD: non-CF: -0.8 (SEM 0.7) mV; CF: -3.6 (0.5) mV) and isoprenaline (non-CF: 1.5 (0.6) mV; CF: -2.9 (0.6) mV) differentiated the two groups of subjects, but there was considerable overlap of values. Perfusion with a low chloride solution (non-CF: 12.6 (1.2) mV; CF: 0.6 (0.4) mV), as well as subsequent perfusion with isoprenaline (non-CF: 10.0 (1.1) mV; CF: -1.4 (0.4) mV) allowed clear separation of the two groups, with no overlap of values. Some CF subjects showed a transient hyperpolarization to these stimuli, which could clearly be differentiated from the sustained responses seen in non-cystic fibrosis subjects.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				B. Lubamba, H. Lecourt, J. Lebacq, P. Lebecque, H. De Jonge, P. Wallemacq, and T. Leal Preclinical Evidence that Sildenafil and Vardenafil Activate Chloride Transport in Cystic Fibrosis Am. J. Respir. Crit. Care Med., March 1, 2008; 177(5): 506 - 515. [Abstract] [Full Text] [PDF]

				J. C Davies, E. W F W Alton, and A. Bush Cystic fibrosis BMJ, December 15, 2007; 335(7632): 1255 - 1259. [Full Text] [PDF]

				S. M. Rowe, F. Accurso, and J. P. Clancy Detection of Cystic Fibrosis Transmembrane Conductance Regulator Activity in Early-Phase Clinical Trials Proceedings of the ATS, August 1, 2007; 4(4): 387 - 398. [Abstract] [Full Text] [PDF]

				A. M. Li, S. Sonnappa, C. Lex, E. Wong, A. Zacharasiewicz, A. Bush, and A. Jaffe Non-CF bronchiectasis: does knowing the aetiology lead to changes in management? Eur. Respir. J., July 1, 2005; 26(1): 8 - 14. [Abstract] [Full Text] [PDF]

				J. C. Davies, M. Davies, D. McShane, S. Smith, S. Chadwick, A. Jaffe, R. Farley, L. Collins, A. Bush, M. Scallon, et al. Potential Difference Measurements in the Lower Airway of Children with and without Cystic Fibrosis Am. J. Respir. Crit. Care Med., May 1, 2005; 171(9): 1015 - 1019. [Abstract] [Full Text] [PDF]

				M. G. Davies, D. M. Geddes, and E. W. F. W. Alton The Effect of Varying Tonicity on Nasal Epithelial Ion Transport in Cystic Fibrosis Am. J. Respir. Crit. Care Med., April 1, 2005; 171(7): 760 - 763. [Abstract] [Full Text] [PDF]

				P G Noone and K W Southern Unravelling salt transport in cystic fibrosis Thorax, November 1, 2004; 59(11): 916 - 917. [Full Text] [PDF]

				I Fajac, D Hubert, D Guillemot, I Honore, T Bienvenu, F Volter, J Dall'Ava-Santucci, and D J Dusser Nasal airway ion transport is linked to the cystic fibrosis phenotype in adult patients Thorax, November 1, 2004; 59(11): 971 - 976. [Abstract] [Full Text] [PDF]

				D. B. Salinas, N. Pedemonte, C. Muanprasat, W. F. Finkbeiner, D. W. Nielson, and A. S. Verkman CFTR involvement in nasal potential differences in mice and pigs studied using a thiazolidinone CFTR inhibitor Am J Physiol Lung Cell Mol Physiol, November 1, 2004; 287(5): L936 - L943. [Abstract] [Full Text] [PDF]

				K W Southernl and D Peckham Establishing a diagnosis of cystic fibrosis Chronic Respiratory Disease, October 1, 2004; 1(4): 205 - 210. [Abstract] [PDF]

				P. G. Middleton, K. A. Pollard, E. Donohoo, J. R. Wheatley, D. M. Geddes, and E. W. Alton Airway Surface Liquid Calcium Modulates Chloride Permeability in the Cystic Fibrosis Airway Am. J. Respir. Crit. Care Med., November 15, 2003; 168(10): 1223 - 1226. [Abstract] [Full Text] [PDF]

				H. L. Wallace, P. M. Barker, and K. W. Southern Nasal Airway Ion Transport and Lung Function in Young People with Cystic Fibrosis Am. J. Respir. Crit. Care Med., September 1, 2003; 168(5): 594 - 600. [Abstract] [Full Text] [PDF]

				M. P. Boyle, M. Diener-West, L. Milgram, M. Knowles, C. Foy, P. Zeitlin, and T. Standaert A Multicenter Study of the Effect of Solution Temperature on Nasal Potential Difference Measurements Chest, August 1, 2003; 124(2): 482 - 489. [Abstract] [Full Text] [PDF]

				H. Mairbaurl, J. Weymann, A. Mohrlein, E. R. Swenson, M. Maggiorini, J. S. R. Gibbs, and P. Bartsch Nasal Epithelium Potential Difference at High Altitude (4,559 m): Evidence for Secretion Am. J. Respir. Crit. Care Med., March 15, 2003; 167(6): 862 - 867. [Abstract] [Full Text] [PDF]

				P. LEBECQUE, T. LEAL, C. DE BOECK, M. JASPERS, H. CUPPENS, and J.-J. CASSIMAN Mutations of the Cystic Fibrosis Gene and Intermediate Sweat Chloride Levels in Children Am. J. Respir. Crit. Care Med., March 15, 2002; 165(6): 757 - 761. [Abstract] [Full Text] [PDF]

				A. HEBESTREIT, U. KERSTING, B. BASLER, R. JESCHKE, and H. HEBESTREIT Exercise Inhibits Epithelial Sodium Channels in Patients with Cystic Fibrosis Am. J. Respir. Crit. Care Med., August 1, 2001; 164(3): 443 - 446. [Abstract] [Full Text] [PDF]

				A Jaffé, A Bush, D M Geddes, and E W F W Alton Prospects for gene therapy in cystic fibrosis Arch. Dis. Child., March 1, 1999; 80(3): 286 - 289. [Full Text]

				C J TAYLOR; Chronic pancreatitis and mutations of the cystic fibrosis gene Gut, January 1, 1999; 44(1): 8 - 9. [Full Text] [PDF]

				S. N. Smith, P. G. Middleton, S. Chadwick, A. Jaffe, K. A. Bush, S. Rolleston, R. Farley, S. J. Delaney, B. Wainwright, D. M. Geddes, et al. The In Vivo Effects of Milrinone on the Airways of Cystic Fibrosis Mice and Human Subjects Am. J. Respir. Cell Mol. Biol., January 1, 1999; 20(1): 129 - 134. [Abstract] [Full Text]

				N. Sharer, M. Schwarz, G. Malone, A. Howarth, J. Painter, M. Super, and J. Braganza Mutations of the Cystic Fibrosis Gene in Patients with Chronic Pancreatitis N. Engl. J. Med., September 3, 1998; 339(10): 645 - 652. [Abstract] [Full Text] [PDF]

				U. PRADAL, C. CASTELLANI, A. DELMARCO, and G. MASTELLA Nasal Potential Difference in Congenital Bilateral Absence of the Vas Deferens Am. J. Respir. Crit. Care Med., September 1, 1998; 158(3): 896 - 901. [Abstract] [Full Text] [PDF]

				P. G Middleton and E. W F W Alton Gene therapy for cystic fibrosis: which postman, which box? Thorax, March 1, 1998; 53(3): 197 - 199. [Abstract] [Full Text]

				R. G. Crystal Transfer of Genes to Humans: Early Lessons and Obstacles to Success Science, October 20, 1995; 270(5235): 404 - 410. [Abstract] [PDF]

				M. R. Knowles, K. W. Hohneker, Z. Zhou, J. C. Olsen, T. L. Noah, P.-C. Hu, M. W. Leigh, J. F. Engelhardt, L. J. Edwards, K. R. Jones, et al. A Controlled Study of Adenoviral-Vector-Mediated Gene Transfer in the Nasal Epithelium of Patients with Cystic Fibrosis N. Engl. J. Med., September 28, 1995; 333(13): 823 - 831. [Abstract] [Full Text] [PDF]